Solventum Corporation (NYSE:SOLV) Receives $90.83 Average Target Price from Analysts

Solventum Corporation (NYSE:SOLV) has been assigned an average recommendation of “Hold” from the fourteen ratings firms that are currently covering the firm, Marketbeat reports. One research analyst has rated the stock with a sell rating, six have issued a hold rating and seven have assigned a buy rating to the company. The average 12 month price target among analysts that have updated their coverage on the stock in the last year is $90.8333.

Several research firms recently weighed in on SOLV. Piper Sandler restated an “overweight” rating on shares of Solventum in a research report on Wednesday, December 17th. Wall Street Zen cut Solventum from a “buy” rating to a “hold” rating in a research note on Saturday, February 7th. Weiss Ratings restated a “hold (c)” rating on shares of Solventum in a research report on Tuesday, January 27th. KeyCorp upgraded Solventum from a “sector weight” rating to an “overweight” rating and set a $97.00 price target on the stock in a report on Monday, January 26th. Finally, Mizuho set a $100.00 price objective on Solventum and gave the stock an “outperform” rating in a research report on Tuesday, January 20th.

Institutional Trading of Solventum

Institutional investors have recently bought and sold shares of the business. Hilltop National Bank boosted its holdings in Solventum by 71.3% during the fourth quarter. Hilltop National Bank now owns 310 shares of the company’s stock worth $25,000 after buying an additional 129 shares during the last quarter. Measured Wealth Private Client Group LLC acquired a new stake in shares of Solventum in the 3rd quarter valued at approximately $25,000. Deseret Mutual Benefit Administrators boosted its stake in Solventum by 78.7% during the 3rd quarter. Deseret Mutual Benefit Administrators now owns 370 shares of the company’s stock worth $27,000 after acquiring an additional 163 shares during the last quarter. JNBA Financial Advisors grew its holdings in Solventum by 205.4% during the fourth quarter. JNBA Financial Advisors now owns 339 shares of the company’s stock valued at $27,000 after purchasing an additional 228 shares during the period. Finally, CYBER HORNET ETFs LLC bought a new stake in Solventum in the second quarter valued at approximately $28,000.

Solventum Trading Up 1.6%

Shares of NYSE SOLV opened at $74.94 on Friday. Solventum has a 1-year low of $60.70 and a 1-year high of $88.20. The company has a 50-day moving average of $79.61 and a two-hundred day moving average of $76.15. The company has a market cap of $13.00 billion, a PE ratio of 8.63, a P/E/G ratio of 6.77 and a beta of 0.35. The company has a current ratio of 1.50, a quick ratio of 1.14 and a debt-to-equity ratio of 1.03.

Solventum announced that its board has authorized a share buyback program on Thursday, November 20th that allows the company to buyback $1.00 billion in shares. This buyback authorization allows the company to purchase up to 7.5% of its shares through open market purchases. Shares buyback programs are usually an indication that the company’s board of directors believes its stock is undervalued.

Solventum Company Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration. The Medsurg segment is a provider of solutions including advanced wound care, I.V. site management, sterilization assurance, temperature management, surgical supplies, stethoscopes, and medical electrodes.